Company / EPS (Diluted)
Vivos Therapeutics, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.22
FY2025
5-year range
-$25.90 / -$1.40
FY2021-FY2025
Trend
+80.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-25.90 to $-2.22 over the past 2 years.
Based on SEC 10-K filings.
-2.22 in FY2025.
Improved from $-25.90 to $-2.22 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 80.1% year-over-year.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.22 | +80.1% |
| FY2024 | -$11.14 | +57.0% |
| FY2023 | -$25.90 | - |
| FY2022 | - | - |
| FY2021 | -$1.40 | -47.4% |
| FY2020 | -$0.95 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026